Capricorn Technologies GmbH has taken the next step in its development. By founding NuCell GmbH, it has expanded its research portfolio with a groundbreaking new product: AEX-1.
The AEX-1 cell line was developed by co-culturing Vero cells with the amniotic membranes of chicken embryos in serum-free OptiPro medium. This innovative process has resulted in a cell line with distinct morphology and properties compared to the original Vero cells.
A key feature of AEX-1 is its ability to support robust replication of multiple influenza strains at exceptionally low infection multiplicities while enabling the high-efficiency rescue of influenza viruses via plasmid transfection. Notably, AEX-1 cells produce influenza A and B virus titres comparable to those obtained in embryonated chicken eggs, presenting a promising platform for efficient and scalable vaccine production.
Beyond vaccine manufacturing, AEX-1 cells serve as an excellent substrate for virus isolation from clinical samples, offering significant advantages for diagnostic applications. These adherent cells are available as a fully characterised working cell bank, with NuCell holding a patent application for their development and commercialisation.
Studies in nude mice have already demonstrated an absence of tumorigenic activity.
NuCell GmbH will present this project at BioEurope Milano in March 2025.
Leave a Reply